Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

Casino workers, labor leaders and public health advocates have been pushing to add casinos to the state's indoor smoking ban ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...